The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

As a receptor tyrosine kinase of insulin receptor (IR) subfamily, anaplastic lymphoma kinase
(ALK) has been validated to play important roles in various cancers, especially anaplastic …

Introduction At the prior data cutoff (February 9, 2017) the ALEX trial showed superior
investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in …

Background Ensartinib is a potent new-generation ALK inhibitor with high activity against a
broad range of known crizotinib-resistant ALK mutations and CNS metastases. We aimed to …

Located in the west Pacific between Japan and the Philippines, the Republic of China has a
population of more than 23 million people. Malignant tumors are the leading cause of death …

A series of novel anaplastic lymphoma kinase (ALK) degraders were designed and
synthesized based on proteolysis-targeting chimera (PROTAC) technology by linking two …

The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm
shift over the last decade. Better molecular characterization of the disease has led to the …

Updated efficacy and safety data from the global phase III ALEX study of alectinib (AL) versus
crizotinib (CZ) in untreated adv Page 1 Updated efficacy and safety data from the global phase …

Six ALK TKIs (crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib) have received
first-line treatment indication of advanced ALK+ NSCLC in various countries. In Ba/F3 cells …

Brain metastases (BM) are common in non-small cell lung cancer patients including in
molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They …